Immune Profiling Panel
Helping Your Research
Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.
- Comprehensive profiling of the immune response optimized for immuno-oncology research
- Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
- Assess mechanistic pathway activity for single or combination studies
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- Multi-analyte analysis with Vantage 3D™ Assays
The nCounter PanCancer Immune Profiling Panel is for cancer researchers that need more markers than is practical for RT-qPCR but don’t want the broad approach that next-gen sequencing (NGS) offers. The Panel is fully compatible with clinically relevant sample types such as fresh-frozen (FF) tissue, formalin-fixed, paraffin-embedded (FFPE) tumor sections, isolated immune cell populations such as PBMCs, and cell lysates. The panel may be used in conjunction with nCounter Panel Plus products for additional flexibility in experimental design.
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma
Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.